Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ligand Pharmaceuticals Incorporated

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND TVTX
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand to Hold Investor and Analyst Day on December 13
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Reports Third Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Announces Completion of OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Distribution of OmniAb Complete and Business Combination Closed
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand to Report Third Quarter Financial Results on November 7
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
OmniAb Business Combination Approved by APAC Shareholders
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers AHPA LGND
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers AHPA LGND
Ligand Reports Second Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers AHPA LGND
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand to Report Second Quarter Financial Results on August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Reports First Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers AHPA LGND
Ligand to Report First Quarter Financial Results on May 4
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers AHPA LGND
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand to Report Fourth Quarter Financial Results on February 17
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand and GSK Expand Global Collaboration and License Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Reports Third Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Ligand to Report Third Quarter Financial Results on November 9, 2021
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Tickers LGND
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.